{"schema_version":"1","generated_at":"2026-11-10T13:40:52.065Z","data_as_of":null,"url":"https://www.findmykol.com/kol/steven-yu","json_url":"https://www.findmykol.com/kol/steven-yu/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"steven-yu","name":"Steven Yu","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"University of California, San Francisco","institution_url":"https://www.findmykol.com/institution/university-of-california-san-francisco","city":"Fountain Valley","state":"CA","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1659643682","orcid":"0009-0004-1099-590X","openalex":"A5066277505"},"summary":"Steven Yu is an Oncology physician affiliated with University of California, San Francisco. OpenAlex indexes 24 publications with 1,017 citations (h-index 10).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":24,"cited_by_count":1017,"h_index":10,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":96,"program_years":{"first":2021,"last":null},"rows_total":239,"shown":3,"withheld":236,"rows":[{"payer":"Merck Sharp & Dohme LLC","program_year":2025,"amount_usd":507.67,"payment_count":18,"source_url":"https://openpaymentsdata.cms.gov/search?query=1659643682"},{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":461.95,"payment_count":18,"source_url":"https://openpaymentsdata.cms.gov/search?query=1659643682"},{"payer":"Novartis Pharmaceuticals Corporation","program_year":2025,"amount_usd":365.28,"payment_count":14,"source_url":"https://openpaymentsdata.cms.gov/search?query=1659643682"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1659643682","source":"payments"},"prescribing":{"data_year":2024,"areas_total":8,"areas_shown":3,"areas":[{"area":"Metabolism & gastrointestinal","share_pct":46.9,"classes_total":2,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"mixed","share_pct":46.3,"drugs":[{"name":"Ondansetron hydrochloride","share_pct":96},{"name":"Ondansetron Hcl","share_pct":2.9},{"name":"Ondansetron Odt","share_pct":1.1}],"max_beneficiaries":null},{"class":"Proton pump inhibitor","setting":"prescribed","share_pct":0.6,"drugs":[{"name":"Omeprazole","share_pct":100}],"max_beneficiaries":null}]},{"area":"Sensory organs","share_pct":37.5,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"mixed","share_pct":37.5,"drugs":[{"name":"Dexamethasone sodium phosphate","share_pct":97.9},{"name":"Dexamethasone Sodium Phosphate","share_pct":1.1},{"name":"Dexamethasone","share_pct":1}],"max_beneficiaries":null}]},{"area":"Cancer & immunology","share_pct":8.6,"classes_total":9,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":2,"drugs":[{"name":"Tagrisso","share_pct":37.1},{"name":"Imatinib Mesylate","share_pct":25.7},{"name":"Cabometyx","share_pct":20},{"name":"Calquence","share_pct":17.1}],"max_beneficiaries":null},{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":1.4,"drugs":[{"name":"Anastrozole","share_pct":68.8},{"name":"Letrozole","share_pct":31.2}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":93.1,"facility_pct":6.9},"source":"medicare"},"publications":{"total":24,"shown":5,"withheld":19,"matched_by":"OpenAlex author record","recent":[{"title":"1000P Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC)","year":2023,"journal":"Annals of Oncology","source_url":"https://doi.org/10.1016/j.annonc.2023.09.2144","status":"verified"},{"title":"A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer","year":2017,"journal":"Clinical Genitourinary Cancer","source_url":"https://doi.org/10.1016/j.clgc.2017.06.002","status":"verified"},{"title":"Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.","year":2017,"journal":"PubMed","status":"verified"},{"title":"Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment.","year":2017,"journal":"PubMed","status":"verified"},{"title":"A phase II trial of zoptarelin doxorubicin in castration- and taxane-resistant prostate cancer.","year":2017,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2017.35.6_suppl.210","status":"verified"}],"source":"works"},"contact":{"address_1":"11180 WARNER AVE STE 351","city":"Fountain Valley","state":"CA","zip":"927087516","phone":"714-698-0300","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1659643682","source":"identity"},"similar":[{"name":"Talmadge King","slug":"talmadge-king","institution":"University of California, San Francisco","specialty":"Pulmonary Disease","url":"https://www.findmykol.com/kol/talmadge-king","json_url":"https://www.findmykol.com/kol/talmadge-king/profile.json"},{"name":"Adil Daud","slug":"adil-daud","institution":"University of California, San Francisco","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/adil-daud","json_url":"https://www.findmykol.com/kol/adil-daud/profile.json"},{"name":"Emmanuelle Waubant","slug":"emmanuelle-waubant","institution":"University of California, San Francisco","specialty":"Neurology","url":"https://www.findmykol.com/kol/emmanuelle-waubant","json_url":"https://www.findmykol.com/kol/emmanuelle-waubant/profile.json"},{"name":"Peter Ganz","slug":"peter-ganz","institution":"University of California, San Francisco","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/peter-ganz","json_url":"https://www.findmykol.com/kol/peter-ganz/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":236,"publications":19}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2025-05-21","provider_certified":"2025-05-21","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}